Drugs /

anti-flt3 monoclonal antibody 4g8-sdiem

Back to Drugs List

Overview

NCI Definition [1]:
A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.

Clinical Trials

View Clinical Trials for anti-flt3 monoclonal antibody 4g8-sdiem

Anti-flt3 monoclonal antibody 4g8-sdiem has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating anti-flt3 monoclonal antibody 4g8-sdiem, 1 is phase 1/phase 2 (1 open).

FLT3 Expression, FLT3 Overexpression, and NPM1 Mutation are the most frequent biomarker inclusion criteria for anti-flt3 monoclonal antibody 4g8-sdiem clinical trials.

Acute myeloid leukemia is the most common disease being investigated in anti-flt3 monoclonal antibody 4g8-sdiem clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Anti-Flt3 Monoclonal Antibody 4g8-Sdiem
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating anti-flt3 monoclonal antibody 4g8-sdiem and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
flysyn, 4g8-sdiem
NCIT ID [1]:
C129376

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.